Table 2.
ER, PR and HER2 Expression Conversion During Metastasis
| Receptor Status | Cases | Percentage | |
|---|---|---|---|
| ER | + to − | 40 | 14.81% |
| − to + | 16 | 5.93% | |
| + | 143 | 52.96% | |
| − | 71 | 21.3% | |
| Concordance | 214 | 79.25% | |
| Discordance | 56 | 20.70% | |
| PR | + to − | 72 | 26.67% |
| − to + | 30 | 11.11% | |
| + | 87 | 32.22% | |
| − | 81 | 30.00% | |
| Concordance | 168 | 62.22% | |
| Discordance | 102 | 37.78% | |
| HER2 | + to − | 11 | 4.07% |
| − to + | 20 | 7.41% | |
| + | 63 | 23.33% | |
| - | 126 | 46.67% | |
| Concordance | 189 | 70.00% | |
| Discordance | 31 | 11.48% | |
| − to not sure | 28 | 10.37% | |
| + to not sure | 22 | 8.15% |
Notes: Frequencies of receptor changes between primary diagnosis and recurrent disease are shown for estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor. + to −, loss in expression; − to +, gains in expression; +, Persistent positivity; −, Persistent negativity.